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Accumulation of protein aggregates is a histopathological hallmark of several
neurodegenerative diseases, but in most cases the aggregation occurs without defined
mutations or clinical histories, suggesting that certain endogenous metabolites can
promote aggregation of specific proteins. One example that supports this hypothesis
is dopamine and its metabolites. Dopamine metabolism generates several oxidative
metabolites that induce aggregation of α-synuclein, and represents the main etiology of
Parkinson’s diseases. Because dopamine and its metabolites are unstable and can be
highly reactive, we investigated whether these molecules can also affect other proteins
that are prone to aggregate, such as cellular prion protein (PrPC). In this study, we
showed that dopamine treatment of neuronal cells reduced the number of viable cells
and increased the production of reactive oxygen species (ROS) as demonstrated in
previous studies. Overall PrPC expression level was not altered by dopamine treatment,
but its unglycosylated form was consistently reduced at 100μM of dopamine. At the
same concentration, the level of phosphorylated mTOR and 4EBP1 was also reduced.
Moreover, dopamine treatment decreased the solubility of PrPC, and increased its
accumulation in autophagosomal compartments with concomitant induction of LC3-II and
p62/SQSTM1 levels. In vitro oxidation of dopamine promoted formation of high-order
oligomers of recombinant prion protein. These results suggest that dopamine metabolites
alter the conformation of PrPC, which in turn is sorted to degradation pathway, causing
autophagosome overload and attenuation of protein synthesis. Accumulation of PrPC
aggregates is an important feature of prion diseases. Thus, this study brings new insight
into the dopamine metabolism as a source of endogenous metabolites capable of altering
PrPC solubility and its subcellular localization.
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INTRODUCTION
Aberrant protein aggregation is a common hallmark of many
neurodegenerative diseases, while a specific protein predomi-
nantly aggregates in each type of diseases (Brundin et al., 2010).
Mutations that alter amino acid sequence or modifications of side
chains by reactivemolecules can disrupt the native fold (Tyedmers
et al., 2010; Petrov and Zagrovic, 2011). Considering that pro-
teins perform numerous biological activities, the accumulation of
their aggregates can be toxic and effective clearance of structurally
altered proteins can be essential for cellular survival (Tyedmers
et al., 2010).
Abbreviations: ROS, Reactive oxygen species; PrPC, Cellular prion protein; PrPSc,
abnormal prion protein; SDS, Sodium dodecyl sulfate; mTOR, Mammalian tar-
get of rapamycin; 4EBP1, 4E binding protein 1; ER, Endoplasmic reticulum;
eIF2-α, Eukariotic initiation factor 2-α; p62/SQSTM1, Sequestosome 1; LC3,
Microtubule-associated protein 1 light chain 3; TSE, Transmissible spongiform
encephalopathies.
Most cases of neurodegenerative diseases are idiopathic and
protein aggregation can occur without defined mutations or clin-
ical histories that clearly justify the manifestation of the diseases
(Alkhuja, 2013; Musiek and Schindler, 2013). This observation
raises the possibility that certain endogenous metabolites can
induce protein misfolding, and protein aggregates may accu-
mulate upon excessive formation of such metabolites and/or
failure of degradation pathways (Morris, 2013). For instance,
reactive oxygen species (ROS) are produced as byproducts of
several endogenous metabolic pathways, such as mitochondrial
respiration and oxidase catalyzed reactions, which include the
metabolism of catecholamine (Andreyev et al., 2005; Dikalov,
2011; Kodama et al., 2013). Among catecholamines, dopamine
is the one that has the greatest propensity for oxidation (LaVoie
et al., 2005). During dopamine metabolism, ROS are gener-
ated not only by enzymatic reactions but also by auto-oxidation
of dopamine, producing highly reactive dopamine quinone
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(Asanuma et al., 2003). The accumulation of neuromelanin
(which is synthesized from dopamine quinone) throughout the
aging process is an indication of the production of dopamine
quinone in physiological conditions (Herrero et al., 1993; Kim
et al., 2006). Thus, enhanced dopamine metabolism can induce
oxidative stress leading to mitocontrial dysfunction and dis-
turbance in protein quality control system (Chen et al., 2008;
Hastings, 2009). Although dopamine metabolism has been exten-
sively linked to the aggregation of α-synuclein and Parkinson’s
disease (Cappai et al., 2005; Lee et al., 2011), dopamine oxida-
tion can also induce the formation of adducts and aggregates
of other proteins, such as cytoskeleton proteins and mitochon-
drial complexes (Van Laar et al., 2009). Moreover, dopamine can
also oxidize prion protein in vitro in the presence of copper ions
(Shiraishi and Nishikimi, 2002; Shiraishi et al., 2005).
Conformational alteration of cellular prion protein (PrPC) is
an essential event for development of transmissible spongiform
encephalopathies (TSE). However, in its normal conformation,
PrPC plays important roles in cell growth, differentiation and sur-
vival (Linden et al., 2008). Previous studies have demonstrated
that PrPC also possesses anti-oxidant properties, but the mech-
anisms related with this function are still under debate. The
expression of PrPC appears to increase during the oxidative stress
caused by ischemia and antioxidant defense mechanisms appear
to require PrPC expression (McLennan et al., 2004; Beraldo et al.,
2013). Direct reactions between PrPC and ROS have also been
proposed (Bertuchi et al., 2012), suggesting that PrPC might play
roles in scavenging ROS from the extracellular environment. PrPC
is highly expressed in neurons and has flexible N-terminal domain
enriched by amino acid residues that are more susceptible to oxi-
dation (Linden et al., 2008; Abouelatta et al., 2009). Thus, it is
plausible to hypothesize that PrPC can be a preferential target of
ROS in the central nervous system with consequent inactivation
of ROS activity. PrPC appears to participate in the regulation of
dopamine metabolism (Lee et al., 1999; Adjou et al., 2008; Rial
et al., 2014), but the role of PrPC in oxidative stress caused by
dopamine oxidation has not yet been evaluated. In this study,
we investigated the effects of dopamine toxicity on the expres-
sion levels, solubility and subcellular localization of PrPC, with
concomitant analysis of cellular viability, protein synthesis and
degradation pathways.
MATERIALS AND METHODS
ANTIBODIES AND REAGENTS
DMEM Media-Glutamax™-I and fetal bovine serum (FBS)
were purchased from Life Technologies. Dopamine hydrochlo-
ride, thiazolyl blue tetrazolium bromide (MTT) and 2′, 7′-
dichlorofluorescein diacetate (DCFDA) were purchased from
Sigma-Aldrich. Complete Protease Inhibitor cocktail tablets were
purchased from Roche and Pierce™ phosphatase inhibitor mini
tablets were purchased from Thermo Scientific. All primary
antibodies were purchased from Cell Signaling, except anti-
prion SAF32, which was purchased from Cayman. Horseradish
peroxidase conjugated secondary antibodies were purchased
from Sigma-Aldrich and Alexa fluorophore conjugated anti-
bodies and CellROX Green reagent were purchased from Life
Technologies.
N2a CELL CULTURE
N2a cells were maintained at 37◦C in a humidified atmosphere of
5% CO2 in DMEM-Glutamax™-I (Dulbecco’s Modified Eagle’s
Medium) supplemented with 10% FBS, Penicillin (100 U/mL)
and Streptomycin (100μg/mL). For dopamine treatment, 4 ×
104 cells/cm2 were seeded. After 24 h, cells were treated with 50
or 100μM dopamine diluted in DMEM containing 0.5% of FBS
for 24 h.
CELL VIABILITY ASSAY
Cells were treated with dopamine in 96-well plates for 24 h.
After the treatment, cells were incubated with 100μl of 1.2mM
MTT diluted in Krebs solution (NaCl 126mM, KCl 2.5mM,
NaHCO3 25mM, NaH2PO4 1.2mM, MgCl2 1.2mM, CaCl2
2.5mM, D-glucose 10mM) for 2 h. The MTT formazan were sol-
ubilized in 100μl of DMSO. Insoluble materials were removed
by centrifugation at 20,000 g for 2min and absorbance of super-
natant was measured at 540 nm.
ROS MEASUREMENT
Cells were treated with dopamine in 96-well plates for 24 h.
After the treatment, cells were incubated with 10μM of DCFDA
or 5μM CellRox Green in DMEM 0.5% FBS for 30min. After
washing twice with PBS or Krebs solution, the fluorescence was
measured using plate reader (Bio-Tek). CellRox Green was also
analyzed by Operetta high content screening system (Perkin
Elmer).
WESTERN BLOT
Cells were lysed with lysis buffer (Tris 100mM, pH 8.0, NaCl
130mM, EDTA 10mM, Triton X-100 1%, sodium deoxycholate
0.5%, complete protease inhibitor cocktail and Pierce phos-
phatase inhibitor mini tablet), and post-nuclear supernatants
(PNS) were collected. The protein content in PNS was quan-
tified using BCA protein assay kit (Thermo Scientific Pierce).
Equal amounts of proteins were resolved by SDS-PAGE and
transferred to PVDF membrane. For immunodetection, mem-
branes were incubated with TBS-T (Tris 50mM, NaCl 150mM,
Tween-20 0.1% pH 7.4) containing 5% BSA for 1 h. Then, the
membranes were incubated with primary antibody for 1 h at
room temperature or for 16 h at 4◦C, then washed three times
with TBS-T. Secondary antibody conjugated with peroxidase and
SuperSignal™ West Pico Chemiluminescent Substrate were used
to detect antigens labeled with specific antibodies. Images were
digitalized and quantified using Alliance mini 4m (UVITEC
Cambridge). For each protein, at least three independent exper-
iments were performed. In every experiment, the band intensity
of the proteins of interest (PI) was normalized by the intensity
of the GAPDH bands. Western blot is semi-quantitative assay
and direct comparison of PI/GAPDH ratio between independent
experiments is not possible. Thus, in order to enable this com-
parison, the average of PI/GAPDH ratio of three experimental
groups (cells treated with 0, 50, and 100μM of dopamine) was
set as 100%, and the percentage of each group was calculated in
each independent experiment. The mean percentage of all inde-
pendent experiments was plotted with respective 95% confidence
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interval (CI95). An example of PrPC expression analysis was
shown in supplementary data.
ULTRACENTRIFUGATION
Post-nuclear supernatants were incubated with 1% sarkosyl for
10min on ice, then ultracentrifuged for 2 h at 100,000 × g and at
4◦C. Pellets were dissolved in sample buffer 4x (8% SDS, Tris HCl
250mM, pH 6.8, 40% Glycerol, 0.08mg/ml bromophenol blue
and 1.4M β-mercaptoetanol), and supernatants were incubated
with 4 volumes of methanol for 2 h at −20◦C for protein pre-
cipitation. After centrifugation for 20min at 25,000× g and 4◦C,
methanol precipitated pellets were dissolved in Sample Buffer 4x.
The level of PrPC in each fraction was assessed by western blot.
To combine the results of multiple independent experiments,
percentage of PrPC observed in each sample was calculated con-
sidering the average of six samples (Pellets and supernatants of
0, 50, and 100μM) as 100%. This normalization was necessary
because the absolute value of the band intensity is not comparable
from one blot to another. Themean percentage of all independent
experiments was plotted with respective CI95.
PURIFICATION OF BIOTINYLATED CELL SURFACE PROTEINS
Cell surface proteins were biotinylated using Pierce Cell Surface
Protein Isolation Kit (Thermo Scientific). The cells were harvested
at time zero or after 1 h incubation in the presence or absence of
50μM of dopamine. Biotinylated proteins were purified from the
cell lysates using NeutrAvidin-agarose, and PrPC was detected by
western blot using SAF32 antibody.
IMMUNOFLUORESCENCE
Cells were fixed with 3.7% paraformaldehyde diluted in PBS (pH
7) for 5min and then with alkalinized 3.7% paraformaldehyde
(pH 10) for 15min. After washing twice with PBS, excess of
paraformaldehyde was inactivated with glycine 100mM and cells
were permeabilized with Triton X-100 0.1% diluted in PBS for
10min. To avoid unspecific bindings, cells were incubated with
1% BSA diluted in PBS for 1 h and then with primary antibodies
diluted in PBS containing Triton X-100 0.1% for 1 h. After wash-
ing three times with PBS, cells were incubated with secondary
antibody conjugated with Alexa 488 or Alexa 594 fluorophore
for 1 h and then washed five times with PBS. Average images
of six frames were acquired for each visual field using confocal
microscope (Leica TCS SP8). Images were analyzed using Image J
1.48r. In each image, total area stained by anti-PrPC was defined
as 100% and percentage of the area co-stained by anti-LC3-II
was assessed using Colocalization Threshold plugin with default
parameters (Bolte and Cordelieres, 2006). To estimate the dis-
tribution of PrPC in intracellular vesicles with distinct sizes, we
counted the number of PrPC-positive particles and then catego-
rized them by their size. The percentage of each category was
calculated in relation to total number of particles counted in each
group.
OLIGOMERIZATION OF RECOMBINANT PrP (rPrP)
rPrP was prepared as described elsewhere (Zahn et al., 1997). The
oligomerization was performed in 20μl of Tris buffer (10mM
pH 7.4) containing 10μg rPrP and dopamine at designated
concentrations. This mixture was incubated for 24 h at 37◦C
protected from the light unless otherwise specified. Sodium
metabisulfite (400μM)was added whenever necessary. The prod-
uct of oligomerization was separated in 4–20% gradient SDS
polyacrylamide gel and revealed by silver staining.
STATISTICAL ANALYSIS
All experiments, except ROS measurement and biotinylation of
cell surface proteins, were repeated 3–5 times. For ROS mea-
surement, one experiment was performed in triplicate for each
dye and detection methods. Mean of independent experiments
or replicates was plotted with respective CI95. The groups were
considered different when their CI95 did not overlap. In this cri-
terion, p-values are estimated to be lower than 0.01 (Cumming
et al., 2007).
RESULTS
DOPAMINE ALTERS THE EXPRESSION LEVEL OF
UNGLYCOSYLATED PrPC
Treatment of neuronal cells with high concentration of dopamine
for a prolonged period (typically 24 h) is known to evoke cyto-
toxic effects (Gomez-Santos et al., 2003; Yamakawa et al., 2010).
To evaluate the effect of dopamine cytotoxicity on PrPC, we
treated N2a cells with 50 and 100μM of dopamine for 24 h.
This treatment did not induce morphological alterations, but
cell viability was gradually reduced as dopamine concentration
was increased (Figures 1A,B). Dopamine treatment also induced
ROS production as assessed by CellROX Green reagent and 2′,7′-
dichlorofluorescein diacetate (DCFDA), compounds that show
enhanced fluorescence upon oxidation. Both reagents showed
similar results in high-throughput plate reader (Figure 1C),
but the increase of CellRox fluorescence induced by 50μM of
dopamine was not statistically significant. This subtle difference
between two dyes can be explained by their different reactivity.
CellROX Green was also analyzed by high content cell analyzer.
As shown in Figure 1D, brighter fluorescent spots were observed
in cells treated with 50 and 100μM of dopamine. According to
the manufacturer, this pattern is due to the primary location of
CellROX in the nucleus and mitochondria upon oxidation.
The treatment with 50 and 100μM of dopamine did not
alter the total amount of PrPC (Figures 2A,B). However, the fast-
migrating band (#) was decreased with 100μM of dopamine
(Figures 2A,C). This band probably represents newly synthesized
unglycosylated form rather than N-terminally truncated PrPC
because this band migrated close to 26 kDa marker and was rec-
ognized by SAF32, an antibody that binds to octa-repeat region
located in N-terminal PrPC. The specific reduction of this imma-
ture form can indicate that dopamine toxicity might have affected
protein synthesis. Thus, we verified the level of mTOR (a master
regulator of growth and protein synthesis) together with 4EBP1
(a repressor of cap-dependent translation upon dephosphoryla-
tion). As shown in Figures 3A–D, phosphorylation of mTOR and
4EBP1 was significantly decreased by 100μM of dopamine. Also,
faster migration of total 4EBP1 bands indicated lower degree of
phosphorylation. These data indicate that protein synthesis might
be compromised in this condition. In addition, the expression
level of ER chaperone BiP was increased with 50μMof dopamine
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FIGURE 1 | Dopamine reduced cell viability and increased ROS
production. The morphology of N2a cells was not altered with dopamine
treatment for 24 h (A), but the viability assessed by the formation of
MTT formazan was reduced after dopamine treatment (B). Mean of four
independent experiments was represented with respective CI95 (B). ROS
production was evaluated using CellROX Green reagent and DCFDA.
Fluorescence was measured by high-throughput plate reader and
normalized by total protein contents/well or by cell viability. Mean of
triplicate was plotted with respective CI95 (C). CellROX Green was also
analyzed by high content cell analyzer. Representative field images are
shown (D). ∗no overlap of CI95 between indicated group and control
group (0μM). scale bar = 20μM.
(Figures 3E,F), suggesting augment of misfolded proteins in ER.
However, at 100μM, BiP expression returned to control level
(Figures 3E,F), presumably due to the attenuated protein synthe-
sis. On the other hand, eIF2-α phosphorylation was not altered
by dopamine treatment (Figures 3E,F).
All protein fold changes were calculated based on the load-
ing control GAPDH. Thus, to ensure the constitutive expression
of GAPDH in our experimental conditions, we compared the
GAPDH expression to α-tubulin, another frequently used load-
ing control. As shown in Figure 4, GAPDH expression was not
significantly changed by dopamine treatment.
Altogether, these data indicate that 100μMof dopamine com-
promises cellular viability, redox balance and protein synthesis,
which may affect the synthesis of PrPC.
DOPAMINE REDUCED THE SOLUBILITY OF PrPC AND INDUCED ITS
ACCUMULATION IN AUTOPHAGOSOMES
An intriguing fact is that even with reduced protein synthe-
sis, we did not observe a significant reduction of the mature
form of PrPC. One possibility is that dopamine treatment may
reduce the turnover of PrPC. To test this hypothesis, we biotiny-
lated cell surface protein and observed a turnover of PrPC. After
1 h of incubation, a substantial amount of biotinylated PrPC
was degraded in both dopamine-treated (50μM) and untreated
cells compared to input (Figure 5A, comparing second and third
lane with first lane). However, a higher amount of biotinylated
PrPC remained in dopamine-treated cells compared to untreated
cells, indicating that dopamine treatment reduced PrPC turnover
(Figure 5A, comparing second lane with third lane). To verify
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FIGURE 2 | Dopamine reduced the expression level of
unglycosylated PrPC. Treatment of N2a cells with dopamine for 24 h
did not alter overall expression of PrPC, but reduced the level of
fast-migrating unglycosylated band of PrPC (#, A). The intensity of
total PrPC (B) or fast-migrating band (C) was normalized by respective
GAPDH band. Means of 5 independent experiments were plotted with
respective CI95.
∗
no overlap of CI95 between indicated group and
control group (0μM).
whether this reduced turnover is due to the altered biochem-
ical characteristics, we evaluated the solubility of PrPC in 1%
sarkosyl. As shown in Figure 5B, an increased amount of PrPC
was recovered in insoluble pellet fraction after treatment with
50 and 100μM of dopamine (Figure 5B). To further evaluate
the effects of dopamine on PrPC aggregation, in vitro experi-
ments were conducted using recombinant mouse PrPC (rPrP).
Dopamine induced the formation of SDS-resistant higher-order
oligomers of rPrP in a time and concentration-dependent man-
ner (Figure 5C). Oligomerization was prevented in the presence
of antioxidant (sodium metabisulfite 400μM) (Figure 5C, last
two lanes). These results indicate that oxidative metabolites of
dopamine can induce the accumulation of insoluble PrPC. In
the presence of metabisulfite, monomer rPrP migrated slowly.
Even after reduction of proteins with DTT, sulfhydryl groups can
be readily reoxidized and form disulfide bond (Wall, 1971), and
reduced recombinant PrP migrates more slowly than oxidized
form (Lee and Eisenberg, 2003). Likely, metabisulfite prevented
the reoxidation of sulfydryl groups, resulting in slower migration
(Figure 5C).
Autophagy is one of the pathways that degrade prion pro-
tein (Homma et al., 2014). Since dopamine treatment induced
accumulation of insoluble PrPC, we evaluated whether these
aggregates were sorted to autophagosomes, labeled by LC3-II
(an autophagosome membrane associated protein). As shown in
Figure 6, the degree of colocalization between PrPC and LC3-II
was increased by dopamine treatment (Figures 6, 7A). Of note,
the intracellular organelles that contained PrPC were frequently
enlarged in cells treated with dopamine (Figures 6, 7B) and they
were mostly positive for LC3-II staining (Figure 6).
In addition, treatment of the N2a cells with 100μM of
dopamine increased the levels of p62/SQSTM1 and LC3-II
(Figures 8A,B). The former transports ubiquitinated proteins to
the autophagosome and remains associated to LC3-II, which is
produced by lipidation of LC3-I (Ravikumar et al., 2010). The
accumulation of both proteins occurred without the induction of
Beclin-1, a component of the complex that initiates the formation
of autophagosome (Figures 8A,B) (Ravikumar et al., 2010). Thus,
these data suggest that the accumulation of autophagosomes was
not due to the activation of autophagy, but rather the failure in
further processing of autophagosomal cargo. The immunofluo-
rescence data also showed the accumulation and enlargement of
LC3-II positive-vesicles (Figure 6).
Overall, these results indicate that toxic concentration of
dopamine altered the solubility of PrPC and promoted its accu-
mulation in autophagosomes, affecting autophagic flux and
attenuating protein synthesis.
DISCUSSION
Dopamine is an important neurotransmitter that controls sev-
eral functions such as physical movement, emotional process and
alertness (Kauer and Malenka, 2007). In spite of its importance
in physiology, dopamine metabolism has been pointed out as the
main etiology of Parkinson’s disease due to the inherent instability
and reactivity of dopamine and its metabolites, capable to induce
oxidative damage in biomolecules (Hastings, 2009). In this study,
we demonstrated that dopamine treatment altered the solubil-
ity of PrPC and promoted its accumulation in autophagosomes
in neuronal cells. Auto-oxidation of dopamine also induced the
formation of SDS-resistant oligomers of unglycosylated recom-
binant prion protein. Previous studies have demonstrated that
inhibition of complex glycosylation during synthetic pathway or
expression of unglycosylated PrP facilitated its conversion into
PrPSc (Korth et al., 2000; Winklhofer et al., 2003). In our study,
dopamine induced aggregation of both glycosylated neuronal
PrPC and unglycosylated rPrP, but with different biochemical
characteristics regarding to the resistance to SDS.
Although the conversion of PrPC into abnormal prion protein
(PrPSc) is an essential event for the development of TSE, molec-
ular mechanisms of conformational transition between PrPC and
PrPSc are poorly understood. Nevertheless, previous studies have
demonstrated that PrPSc-like aggregates were found in normal
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FIGURE 3 | Dopamine treatment compromised protein synthesis. The
level of phosphorylated mTOR (p-mTOR) was reduced by 100μM of
dopamine, while total mTOR was not altered (A,B). The level of
phosphorylated 4EBP-1 (p-4EBP-1) and total 4EBP1 was reduced by 100μM
of dopamine (C,D). The level of BiP was induced by 50μM of dopamine,
while the phosphorylated eIF2α (p-eIF2α) was not altered (E,F). Band
intensity of p-mTOR, mTOR, p-4EBP1, total 4EBP1, BiP and p-eIF2α was
normalized by the respective GAPDH band and mean of three independent
experiments was plotted with respective CI95 (B, D, and F). ∗no overlap of
CI95 between indicated group and control group (0μM).
brains at low levels (Yuan et al., 2006). Glycosylation pattern,
retrograde transport from ER to cytosol and inhibition of proteo-
somal activity might contribute to this spontaneous production
of PrPSc-like aggregates (Korth et al., 2000; Yedidia et al., 2001;
Ma and Lindquist, 2002;Winklhofer et al., 2003). The aggregation
of PrPC in response to redox alteration has also been proposed
as a cytoprotective mechanism (Das et al., 2010). However, if
the aggregates are not effectively degraded by autophagy, other
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FIGURE 4 | Validation of GAPDH as loading control. N2a cells were
treated with dopamine at designated concentrations and cell lysates were
used to evaluate the expression levels of GAPDH and α-tubulin in four
independent samples. The band intensity of GAPDH was normalized by the
intensity of α-tubulin. Mean normalized intensity was plotted with respective
CI95.
FIGURE 5 | Dopamine reduced turnover and solubility of PrPC. Cell
surface proteins was biotinylated and chased at time zero (input) or after 1 h
incubation in the presence or absence of 50μM of dopamine. After 1 h,
dopamine treated cells showed higher amount of remaining PrPC compared
to untreated cells (A). After dopamine treatment, insoluble proteins in
sarkosyl 1% were recovered by ultracentrifugation. Higher amounts of PrPC
were recovered in pellet fractions and lower amount in supernatants (SN),
indicating lower solubility (B). Mean band intensity of three independent
experiments was plotted with respective CI95. Dark gray bars represent SN
and light gray bars represent pellet quantification (B). ∗no overlap of CI95
between indicated group and control group (0μM). rPrP (10μg) was
incubated with designated concentration of dopamine (DA) for 24 h or with
400μM of dopamine for indicated times (C). When 400μM of metabisulfite
(#) was added, the oligomerization was prevented (C). rPrP monomer
migrated close to 26 kDa marker. Three independent experiments were
performed and representative images are shown.
proteins might co-aggregate causing cytotoxicity (Das et al.,
2010). In this study, we observed that dopamine treatment
increased the amount of LC3-II and p62/SQSTM1, both involved
in autophagosomal cargo recruitment. Concomitantly, PrPC was
also accumulated in autophagosomes. These data indicate that the
degradation of autophagosomal cargo by lysosome was not effec-
tive. Therefore, it is plausible to speculate that the reduced cell
viability observed after dopamine treatment is at least partially
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FIGURE 6 | Dopamine induced PrPC sorting to autophagosomes. After dopamine treatment, endogenous PrPC (green) and LC3-I/LC3-II (red) was detected
using specific antibodies. Third column shows merged images. Right column shows colocalized pixels in gray scale. Scale bar = 10μm.
FIGURE 7 | Image analysis. Percentage of PrPC-positive area that colocaize
with LC3-II was calculated using colocalization threshold plugins of Image J.
The graphs represent mean of 5 to 6 images with respective CI95 (A). ∗no
overlap of CI95 between indicated group and control group. The area of
PrPC-positive intracellular vesicles was measured in pixel2 using Image J and
was categorized by their area. Percentage of each category was calculated. (B).
Dopamine treated cells (dotted lines) showed lower percentage of smaller
vesicles and higher percentage of vesicles that measuredmore than 0.5 pixel2.
due to the accumulation of PrPC aggregates in autophagosomes.
Similarly, PrPC aggregationmight have negatively affected protein
synthesis since a previous study has demonstrated that protein
synthesis was corrupted in N2a cells infected with prions (Roffe
et al., 2010).
Endocytosis of PrPC can be stimulated by several compounds
such as Cu2+, nucleic acids and heme (Lee et al., 2001, 2007;
Kocisko et al., 2006). An intriguing fact is that these compounds
can alter the structure of PrPC and confer cytotoxicity at high
concentration (Thakur et al., 2011; Macedo et al., 2012). These
findings suggest that PrPC might function as a scavenging recep-
tor for toxic molecules. Dopamine can induce toxicity by rapid
auto-oxidation producing reactive dopamine-quinone (Asanuma
et al., 2003; Chen et al., 2008). Binding of toxic molecules to
PrPC, including dopamine metabolites, might induce structural
alterations, which in turn, may trigger endocytosis for further
degradation. Frequent binding of toxic molecules that cause
conformational alterations of PrPC can eventually overload the
degradation pathways, instigating the accumulation of protein
aggregates.
Certain conditions, such as stress, drug addiction, iron
deficiency, L-DOPA treatment or schizophrenia are known to
increase dopamine metabolism (Nelson et al., 1997; de la Fuente-
Fernandez et al., 2004; Elliott and Beveridge, 2005; Kim et al.,
2005). Our findings raise a possibility that chronic exposure
to these conditions may facilitate PrPC aggregation. Possibly,
dopamine and its oxidative metabolites can have more general
roles in other protein aggregation, but the specificity of the
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FIGURE 8 | Dopamine treatment induced accumulation of
autophagosomes. The level of Beclin-1 was reduced by 50μM of dopamine
and restored to control level at 100μM, while p62/SQSTM1 and LC3-II was
increased by 100μM of dopamine (A). Beclin-1 and LC3-II were analyzed in
the same gradient gel. Band intensity of Beclin-1, p62/SQSTM1, and LC3-II
was normalized by the respective GAPDH band and mean of three
independent experiments was plotted with respective CI95 (B). ∗no overlap
of CI95 between indicated group and control group (0μM).
target can be ruled by subcellular compartmentalization, brain
region specificity and susceptibility of aggregation. Identification
of endogenous metabolites that induce aggregation of a specific
protein can contribute to better understanding of idiopathic neu-
rodegenerative diseases and provide new molecular targets for
treatment.
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